Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceclidine SCHEMBL121393 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| (S)-Aceclidine SCHEMBL9146471 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL6237805 | 0.98 | CHRM2 (0.96) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL10574679 | 0.90 | CHRM2 (0.82) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL16933508 | 0.86 | CHRM2 (0.75) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Oxalic Acid SCHEMBL10571388 | 0.85 | CHRM2 (0.74) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| SCHEMBL3743481 | 0.83 | CHRM2 (0.71) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL4140116 | 0.83 | CHRM2 (0.69) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL13724819 | 0.82 | CHRM2 (0.68) | CHRM2CHRM1MEN1CYP2D6KMT2A | |
| Aceclidine SCHEMBL28142116 | 0.82 | CHRM2 (0.68) | CHRM2CHRM1MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| WO-2023202705-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATING PRESBYOPIA | 温州医科大学附属眼视光医院 | 2023-10-26 | — | — | WO | disclosed |
| CN-114588156-A | Ophthalmic preparation and application thereof in treating presbyopia | 温州医科大学附属眼视光医院 | 2022-06-07 | — | — | CN | disclosed |
| EP-3627152-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2020-03-25 | — | — | EP | disclosed |
| CN-105348877-A | Water-proofing agent for tunnel | CHUZHOU SIMAITE COMPOSITE MATERIAL CO LTD | 2016-02-24 | — | — | CN | disclosed |
| EP-2291374-B1 | PROCESS FOR PREPARATION OF SOLIFENACIN AND/OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF OF HIGH PHARMACEUTICAL PURITY | ZAKLADY FARM POLPHARMA SA (PL) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014140318-A1 | IMPROVED PROCESS FOR ACYL TRANSFER REACTIONS | K.H.S. PHARMA HOLDING GMBH (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | ISOCHEM (FR) | 2014-08-14 | — | — | US | disclosed |
| US-20070173528-A1 | Process for preparing solifenacin | TEVA PHARMACEUTICALS USA, INC. | 2007-07-26 | — | — | US | disclosed |
| US-5387409-A | Diagnostic imaging agents, e.g. hypoxic tissue; radiotherapy; kits | BRACCO INTERNATIONAL B.V. (NL) | 1995-02-07 | — | — | US | disclosed |
| EP-0441491-A1 | Boronic acid adducts of rhenium dioxime and technetium-99M dioxime complexes containing a biochemically active group | BRACCO INTERNATIONAL B.V. (NL) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173528-A1 | Process for preparing solifenacin | SUCNR1, OPRL1, CHRNG | CHRM2 57/4885CHRM1 80/4885MEN1 3004/4885 |
| US-20140228575-A1 | Process for the Preparation of Solifenacin and Salts Thereof | NEU3, NEU4, ADRB3 | CHRM2 49/4885CHRM1 47/4885MEN1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.